Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesSafety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Antimicrobial Agents and Chemotherapy, 06/29/09
Spellberg B et al. - Deferasirox was administered for an average of 14 days at 5 to 20 mg/kg of body weight/day. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
Related Articles
A Successful Combined Endovascular and Surgical Treatment of A Cranial Base Mucormycosis With An Associated Internal Carotid Artery Pseudoaneurysm
Neurosurgery, 10/07/09
Relevance Score: 88%
Rhino-Orbital-Cerebral Mucormycosis: A Lethal Complication of Body Dysmorphic Disorder
Ophthalmic Plastic and Reconstructive Surgery, 10/06/09
Relevance Score: 83%
Ulcerative leg nodules in a transplant recipient
Cleveland Clinic Journal of Medicine, 10/16/09
Relevance Score: 82%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibition of Herpes Simplex Virus Type 1 By the Experimental Immunosuppressive Agent Leflunomide
Transplantation, 12/16/09
Use of oseltamivir in children
Canadian Family Physician, 12/16/09
The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor